Edgerton leaves Kodak PACS business

Article

Ron Edgerton has stepped down from his position as general managerof Kodak's Medical Imaging Systems group, the Dallas businessunit that handles the company's efforts in PACS and digital imaging.Edgerton has been replaced by Richard Cimino, who

Ron Edgerton has stepped down from his position as general managerof Kodak's Medical Imaging Systems group, the Dallas businessunit that handles the company's efforts in PACS and digital imaging.Edgerton has been replaced by Richard Cimino, who previously wasgeneral manager of the U.S. northeast region for Kodak HealthImaging, the Dallas unit's parent in Rochester, NY.

Edgerton had replaced Catherine Burzik as head of the Dallasunit when he assumed the position last November. Edgerton previouslywas CFO of the Dallas business, and left the company for a jobin the financial services industry.

Edgerton is the second high-ranking executive to leave Kodak'sPACS effort in the past several months. Shridar Seshadri, responsiblefor strategic planning and archiving, left Kodak in August. Seshadri'sresponsibilities in the archiving sector have been assumed byLori Martin.

Recent Videos
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
Related Content
© 2025 MJH Life Sciences

All rights reserved.